DAFTAR PUSTAKA

1. Foster CS. Stevens-Johnson syndrome: practice essential, background,

pathophysiology. http://emedicine.medscape.com/article/1197450overview. 2014 Apr.29
2. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are
severity variants of the same disease which differs from erythema multiforme.
J Dermatol. 1997 Nov. 24(11):7269. [Medline].
3. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our
current understanding. Allergol Int. 2006 Mar. 55(1):916. [Medline].
4. Djuanda A., Hamzah M. 2010. Ilmu Penyakit Kulit dan Kelamin. Ed.VI.
Jakarta: Fakultas Kedokteran Universitas Indonesia
5. Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ. 2008.
Fitzpatricks Dermatology in General Medicine. 7th Edition. New York:
McGrawHill.
6. Fernando SL, Broadfoot AJ. Prevention of severe cutaneous adverse drug
reactions: the emerging value of pharmacogenetic screening. CMAJ. 2010 Mar
23. 182(5):47680. [Medline]. [Full Text].
7. Hllgren J, TengvallLinder M, Persson M, Wahlgren CF. StevensJohnson
syndrome associated with ciprofloxacin: a review of adverse cutaneous events
reported in Sweden as associated with this drug. J Am Acad Dermatol. 2003
Nov. 49(5 Suppl):S2679.[Medline].
8. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of
StevensJohnson syndrome and toxic epidermal necrolysis in new users of
antiepileptics. Neurology. 2005 Apr 12. 64(7):11348. [Medline].
9. Metry DW, Lahart CJ, Farmer KL, Hebert AA. StevensJohnson syndrome
caused by the antiretroviral drug nevirapine. J Am Acad Dermatol. 2001 Feb.
44(2 Suppl):3547. [Medline].
10. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most
common cause of StevensJohnson syndrome and toxic epidermal necrolysis in
Europe and Israel. J Am Acad Dermatol. 2008 Jan. 58(1):2532. [Medline].
11. Belkahia A, HillaireBuys D, Dereure O, Guillot B, RaisonPeyron N.
StevensJohnson syndrome due to mirtazapine first case. Allergy. 2009 Oct.
64(10):1554. [Medline].
12. Salama M, Lawrance IC. StevensJohnson syndrome complicating adalimumab
therapy in Crohn's disease. World J Gastroenterol. 2009 Sep 21.
15(35):444952. [Medline]. [Full Text].
13. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for StevensJohnson
syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007. 87(2):1448.
[Medline].
14. Hynes AY, Kafkala C, Daoud YJ, Foster CS. Controversy in the use of
highdose systemic steroids in the acute care of patients with StevensJohnson
syndrome. Int Ophthalmol Clin. 2005 Fall. 45(4):2548. [Medline].
15. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in
StevensJohnson syndrome and toxic epidermal necrolysis. Ann Allergy
Asthma Immunol. 2006 Sep. 97(3):27280 quiz 2813, 320. [Medline].
16. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous
reactions associated with the use of human immunodeficiency virus
medications. Acta Derm Venereol. 2003. 83(1):19. [Medline].

17. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous
immunoglobulin therapy in the
treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol.
2003 Aug. 139(8):10519.
[Medline].
18. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson
syndrome: patterns of chronic
ocular disease and the role of systemic immunosuppressive therapy. Br J
Ophthalmol. 2007 Aug.
91(8):104853.
[Medline]. [Full Text].
19. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema
multiforme and StevensJohnson
syndrome. Contribution of perforinpositive
cell infiltration. Arch Dermatol. 1997 Jul. 133(7):8459.
[Medline].
20. Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation
after StevensJohnson
syndrome. Ophthalmology. 1988 Apr. 95(4):45362.
[Medline].
21. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients
with StevensJohnson
syndrome and toxic epidermal necrolysis preceding skin detachment. J
Allergy Clin Immunol. 2008 Nov.
122(5):9921000.
22. Foster CS. Stevens-Johnson syndrome workup: approach consideration,
histologic findings. http://emedicine.medscape.com/article/1197450workup. 2014. Apr 29
23. Foster CS. Stevens-Johnson syndrome treatment and management.
http://emedicine.medscape.com/article/1197450-treatment#showall. 2014 Apr 29

24. BastujiGarin
S, Fouchard N, Bertocchi M, et al. SCORTEN: a severityofillness
score for toxic epidermal
necrolysis. J Invest Dermatol. 2000 Aug. 115(2):14953.
[Medline].
25. de Prost N, IngenHouszOro S, Duong T, et al. Bacteremia in StevensJohnson
syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and
predictive value of skin cultures. Medicine (Baltimore). 2010 Jan. 89(1):2836.

References
1. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our
current understanding. Allergol
Int. 2006 Mar. 55(1):916.
[Medline].
2. Roujeau JC. StevensJohnson
syndrome and toxic epidermal necrolysis are severity variants of the same
disease which differs from erythema multiforme. J Dermatol. 1997 Nov.
24(11):7269.
[Medline].
3. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions
associated with the use of
human immunodeficiency virus medications. Acta Derm Venereol. 2003. 83(1):19.
[Medline].
4. Gruchalla RS. 10. Drug allergy. J Allergy Clin Immunol. 2003 Feb. 111(2
Suppl):S54859.
[Medline].
5. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous
immunoglobulin therapy in the
treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol.
2003 Aug. 139(8):10519.
[Medline].
AssierBonnet
H, Aractingi S, Cadranel J, Wechsler J, Mayaud C, Saiag P. StevensJohnson
syndrome
induced by cyclophosphamide: report of two cases. Br J Dermatol. 1996 Nov.
135(5):8646.
[Medline].
7. De Rojas MV, Dart JK, Saw VP. The natural history of Stevens Johnson
syndrome: patterns of chronic
ocular disease and the role of systemic immunosuppressive therapy. Br J
Ophthalmol. 2007 Aug.
91(8):104853.
[Medline]. [Full Text].
8. Morel E, Escamochero S, Cabaas R, Daz R, Fiandor A, Belln T.
CD94/NKG2C is a killer effector
molecule in patients with StevensJohnson
syndrome and toxic epidermal necrolysis. J Allergy Clin
Immunol. 2010 Mar. 125(3):70310,
710.e1710.

e8. [Medline].
9. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema
multiforme and StevensJohnson
syndrome. Contribution of perforinpositive
cell infiltration. Arch Dermatol. 1997 Jul. 133(7):8459.
[Medline].
10. Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation
after StevensJohnson
syndrome. Ophthalmology. 1988 Apr. 95(4):45362.
[Medline].
11. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients
with StevensJohnson
syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy
Clin Immunol. 2008 Nov.
122(5):9921000.
[Medline].
12. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic
epidermal necrolysis and
StevensJohnson
syndrome: our current understanding. Int Immunopharmacol. 2006 Apr.
6(4):5439.
[Medline].
13. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most
common cause of StevensJohnson
syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad
Dermatol. 2008 Jan. 58(1):2532.
[Medline].
14. Schlienger RG, Shapiro LE, Shear NH. Lamotrigineinduced
severe cutaneous adverse reactions.
Epilepsia. 1998. 39 Suppl 7:S226.
[Medline].
15. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of
StevensJohnson
syndrome and toxic
epidermal necrolysis in new users of antiepileptics. Neurology. 2005 Apr 12.
64(7):11348.
[Medline].
16. Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in
systemic lupus erythematosus.
Autoimmun Rev. 2006 Feb. 5(2):1604.
[Medline].
17. HillebrandHaverkort
ME, Budding AE, bij de Vaate LA, van Agtmael MA. Mycoplasma pneumoniae
infection with incomplete StevensJohnson
syndrome. Lancet Infect Dis. 2008 Oct. 8(10):5867.
[Medline].
18. Sendi P, Graber P, Lepre F, Schiller P, Zimmerli W. Mycoplasma pneumoniae
infection complicated by

severe mucocutaneous lesions. Lancet Infect Dis. 2008 Apr. 8(4):268. [Medline].
19. Hllgren J, TengvallLinder
M, Persson M, Wahlgren CF. StevensJohnson
syndrome associated with
ciprofloxacin: a review of adverse cutaneous events reported in Sweden as
associated with this drug. J Am
Acad Dermatol. 2003 Nov. 49(5 Suppl):S2679.
[Medline].
20. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of
StevensJohnson syndrome and toxic epidermal necrolysis in new users of
antiepileptics. Neurology. 2005 Apr 12. 64(7):11348. [Medline].
21. Metry DW, Lahart CJ, Farmer KL, Hebert AA. StevensJohnson
syndrome caused by the antiretroviral drug
nevirapine. J Am Acad Dermatol. 2001 Feb. 44(2 Suppl):3547.
[Medline].
22. Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most
common cause of StevensJohnson
syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad
Dermatol. 2008 Jan. 58(1):2532.
[Medline].
23. Belkahia A, HillaireBuys
D, Dereure O, Guillot B, RaisonPeyron
N. StevensJohnson
syndrome due to
mirtazapine first
case. Allergy. 2009 Oct. 64(10):1554. [Medline].
24. Salama M, Lawrance IC. StevensJohnson
syndrome complicating adalimumab therapy in Crohn's disease.
World J Gastroenterol. 2009 Sep 21. 15(35):444952.
[Medline]. [Full Text].
25. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for StevensJohnson
syndrome/toxic epidermal
necrolysis. Acta Derm Venereol. 2007. 87(2):1448.
[Medline].
26. Fernando SL, Broadfoot AJ. Prevention of severe cutaneous adverse drug
reactions: the emerging value of
pharmacogenetic screening. CMAJ. 2010 Mar 23. 182(5):47680.
[Medline]. [Full Text].
27. Hynes AY, Kafkala C, Daoud YJ, Foster CS. Controversy in the use of
highdose
systemic steroids in the
acute care of patients with StevensJohnson
syndrome. Int Ophthalmol Clin. 2005 Fall. 45(4):2548.
[Medline].
28. Khalili B, Bahna SL. Pathogenesis and recent therapeutic trends in
StevensJohnson
syndrome and toxic
epidermal necrolysis. Ann Allergy Asthma Immunol. 2006 Sep. 97(3):27280

quiz 2813,
320. [Medline].
29. Meth MJ, Sperber KE. Phenotypic diversity in delayed drug hypersensitivity:
an immunologic explanation.
Mt Sinai J Med. 2006 Sep. 73(5):76976.
[Medline].
30. Strom BL, Carson JL, Halpern AC, et al. A populationbased
study of StevensJohnson
syndrome.
Incidence and antecedent drug exposures. Arch Dermatol. 1991 Jun. 127(6):8318.
[Medline].
31. BastujiGarin
S, Fouchard N, Bertocchi M, et al. SCORTEN: a severityofillness
score for toxic epidermal
necrolysis. J Invest Dermatol. 2000 Aug. 115(2):14953.
[Medline].
32. de Prost N, IngenHouszOro
S, Duong T, et al. Bacteremia in StevensJohnson
syndrome and toxic
epidermal necrolysis: epidemiology, risk factors, and predictive value of skin
cultures. Medicine (Baltimore).
2010 Jan. 89(1):2836.
[Medline].
33. Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy
S, et al. Comprehensive
Survival Analysis of a Cohort of Patients with StevensJohnson
Syndrome and Toxic Epidermal Necrolysis.
J Invest Dermatol. 2013 Feb 7. [Medline].
34. Vera LS, Gueudry J, Delcampe A, et al. In vivo confocal microscopic
evaluation of corneal changes in
chronic StevensJohnson
syndrome and toxic epidermal necrolysis. Cornea. 2009 May. 28(4):4017.
[Medline].
35. Shammas MC, Lai EC, Sarkar JS, Yang J, Starr CE, Sippel KC. Management
of acute StevensJohnson syndrome and toxic epidermal necrolysis utilizing
amniotic membrane and topical corticosteroids. Am J
Ophthalmol. 2010 Feb. 149(2):203213.
e2. [Medline].
36. Tseng SC. Acute management of StevensJohnson
syndrome and toxic epidermal necrolysis to minimize
ocular sequelae. Am J Ophthalmol. 2009 Jun. 147(6):94951.
[Medline].
37. Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Pirard GE.
Immunoregulatory effector cells in
druginduced
toxic epidermal necrolysis. Am J Dermatopathol. 2000 Oct. 22(5):4137.
[Medline].

38. Sotozono C, Ueta M, Koizumi N, et al. Diagnosis and treatment of

StevensJohnson
syndrome and toxic
epidermal necrolysis with ocular complications. Ophthalmology. 2009 Apr.
116(4):68590.
[Medline].
39. Sotozono C, Ueta M, Kinoshita S. Systemic and local management at the
onset of StevensJohnson
syndrome and toxic epidermal necrolysis with ocular complications. Am J
Ophthalmol. 2010 Feb.
149(2):354 author reply 355. [Medline].
40. Araki Y, Sotozono C, Inatomi T, et al. Successful treatment of StevensJohnson
syndrome with steroid
pulse therapy at disease onset. Am J Ophthalmol. 2009 Jun. 147(6):100411,
1011.e1. [Medline].
41. Koh MJ, Tay YK. StevensJohnson
syndrome and toxic epidermal necrolysis in Asian children. J Am Acad
Dermatol. 2010 Jan. 62(1):5460.
[Medline].
42. Patterson R, Dykewicz MS, Gonzalzles A, et al. Erythema multiforme and
StevensJohnson
syndrome.
Descriptive and therapeutic controversy. Chest. 1990 Aug. 98(2):3316.
[Medline].
43. Power WJ, Ghoraishi M, MerayoLloves
J, Neves RA, Foster CS. Analysis of the acute ophthalmic
manifestations of the erythema multiforme/StevensJohnson
syndrome/toxic epidermal necrolysis disease
spectrum. Ophthalmology. 1995 Nov. 102(11):166976.
[Medline].
44. Hebert AA, Bogle MA. Intravenous immunoglobulin prophylaxis for recurrent
StevensJohnson
syndrome. J
Am Acad Dermatol. 2004 Feb. 50(2):2868.
[Medline].
45. Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of
StevensJohnson
syndrome
and toxic epidermal necrolysis: A retrospective study on patients included in the
prospective EuroSCAR
Study. J Am Acad Dermatol. 2008 Jan. 58(1):3340.
[Medline].
46. Pehr K. The EuroSCAR study: cannot agree with the conclusions. J Am Acad
Dermatol. 2008 Nov.
59(5):8989
author reply 899900.
[Medline].

47. Power WJ, Saidman SL, Zhang DS, et al. HLA typing in patients with ocular
manifestations of StevensJohnson
syndrome. Ophthalmology. 1996 Sep. 103(9):14069.
[Medline].
48. FDA Drug Safety Communication. FDA warns of rare but serious skin
reactions with the pain reliever/fever
reducer acetaminophen. Available at
http://www.fda.gov/Drugs/DrugSafety/ucm363041.htm. Accessed:
August 4, 2013.
49. Lowes R. Acetaminophen poses risk for rare but fatal skin reactions.
Medscape Medical News. August 1,
2013. [Full Text].